1. Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment. Issue 2 (19th September 2006) Authors: Russell, A S; Wallenstein, G V; Li, T; Martin, M C; Maclean, R; Blaisdell, B; Gajria, K; Cole, J C; Becker, J-C; Emery, P Journal: Annals of the rheumatic diseases Issue: Volume 66:Issue 2(2007) Page Start: 189 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial. Issue 8 (17th December 2007) Authors: Genant, H K; Peterfy, C G; Westhovens, R; Becker, J-C; Aranda, R; Vratsanos, G; Teng, J; Kremer, J M Journal: Annals of the rheumatic diseases Issue: Volume 67:Issue 8(2008) Page Start: 1084 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Issue 12 (5th January 2009) Authors: Westhovens, R; Robles, M; Ximenes, A C; Nayiager, S; Wollenhaupt, J; Durez, P; Gomez-Reino, J; Grassi, W; Haraoui, B; Shergy, W; Park, S-H; Genant, H; Peterfy, C; Becker, J-C; Covucci, A; Helfrick, R; Bathon, J Journal: Annals of the rheumatic diseases Issue: Volume 68:Issue 12(2009) Page Start: 1870 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Issue 8 (29th November 2007) Authors: Schiff, M; Keiserman, M; Codding, C; Songcharoen, S; Berman, A; Nayiager, S; Saldate, C; Li, T; Aranda, R; Becker, J-C; Lin, C; Cornet, P L N; Dougados, M Journal: Annals of the rheumatic diseases Issue: Volume 67:Issue 8(2008) Page Start: 1096 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Issue 4 (5th October 2007) Authors: Genovese, M C; Schiff, M; Luggen, M; Becker, J-C; Aranda, R; Teng, J; Li, T; Schmidely, N; Le Bars, M; Dougados, M Journal: Annals of the rheumatic diseases Issue: Volume 67:Issue 4(2008) Page Start: 547 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). Issue 3 (23rd November 2009) Authors: Emery, P; Durez, P; Dougados, M; Legerton, C W; Becker, J-C; Vratsanos, G; Genant, H K; Peterfy, C; Mitra, P; Overfield, S; Qi, K; Westhovens, R Journal: Annals of the rheumatic diseases Issue: Volume 69:Issue 3(2010) Page Start: 510 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes. Issue 11 (6th August 2011) Authors: Bathon, J; Robles, M; Ximenes, A C; Nayiager, S; Wollenhaupt, J; Durez, P; Gomez-Reino, J; Grassi, W; Haraoui, B; Shergy, W; Park, S-H; Genant, H; Peterfy, C; Becker, J-C; Covucci, A; Moniz Reed, D; Helfrick, R; Westhovens, R Journal: Annals of the rheumatic diseases Issue: Volume 70:Issue 11(2011) Page Start: 1949 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Issue 6 (19th May 2008) Authors: Wells, G; Becker, J-C; Teng, J; Dougados, M; Schiff, M; Smolen, J; Aletaha, D; van Riel, P L C M Journal: Annals of the rheumatic diseases Issue: Volume 68:Issue 6(2009) Page Start: 954 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗